Having received FDA approval for the Ilesto family of implantable cardioverter-defibrillator (ICD) / cardiac resynchronization therapy defibrillator (CRT-D) devices, BIOTRONIK is launching the Ilesto DX platform in the US. Currently, there are two basic options when it comes to ICD/CRT devices. The first are dual lead systems that are able to pace the atrium and detect both ventricular and atrial signals. Having two wires running to the heart, though, increases the chances of complications. A single lead system, on the other hand, only has right ventricular sensing capabilities to detect arrhythmias and can miss high atrial rates, potentially leading to inappropriate shocks from the implant or even resulting in stroke.
Despite being a single lead system, Biotronik’s Ilesto DX has the capabilities of a dual lead device and is able to sense and interpret atrial electrical signals without the second lead. Amplifying the signal of the floating atrial dipole from the Linoxsmart S DX ICD lead allows the Ilesto DX to accurately sense atrial activity.
The other major benefit of the Ilesto DX is a smaller profile. Its makeover resulted in a 15% size reduction with 29% fewer parts compared to Biotronik’s Lumax 540 VR-T DX, with no loss in expected device life or functionality. As with the previous Ilesto 7 series that Medgadget has already reported on, the Ilesto DX is equipped with Biotronik Home Monitoring, allowing physicians to monitor patients continuously.
Flashbacks: BIOTRONIK Ilesto 7 ICD/CRT-Ds with Home Monitoring Cleared in U.S…; BIOTRONIK’s Releases Ilesto 7 ICD/CRT-D’s in US…; BIOTRONIK’s Ilesto 7 Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators Cleared in EU…
Press release: Following FDA Approval of Ilesto ICD/CRT-D Devices, BIOTRONIK Launches Ilesto DX…
Product page: Ilesto 7…